Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    0.00 (0.00%)
Bid:
143.00
Ask:
145.00
Spread: 2.00 (1.399%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Interim Management Statement

19 Apr 2010 07:00

RNS Number : 3236K
Xaar PLC
19 April 2010
Β 

ο»Ώ

Β 

Β 

Β 

FOR IMMEDIATE RELEASE

19 April 2010

Β 

Β 

Β 

Xaar plc

Β 

Β 

INTERIM MANAGEMENT STATEMENT

Β 

Β 

Xaar plc ("Xaar" or "the Group"), the inkjet printing technology group headquartered in Cambridge, is providing an Interim Management Statement covering trading from 1 January 2010 to 31 March 2010.

Β 

Trading and margins for the first quarter of the year were in line with the Board's expectations. Sales of Platform 1 ("P1") products have shown more stability than seen in recent periods and the increased demand for Platform 3 ("P3") products, first reported for the fourth quarter of last year, has continued. During Q1 2010, P3 demand continued to grow; the company is investing to increase output from the Huntingdon plant by mid-year.

Β 

The increase in P3 sales continues to be driven by volume sales into the industrial and packaging markets. We continue to work with our customers in these and other end markets to deliver levels of performance to allow them to move their printing machinery products to volume launch. We are still incurring some additional costs associated with new product introductions; however these are expected to reduce later this year as previously stated.

Β 

The consolidation of the Group's manufacturing facilities into a single plant in Huntingdon, England continues to progress according to schedule with the costs and benefits of the project remaining in line with the original plan.

Β 

The Group's balance sheet is strong with net cash at 31 March 2010 of Β£9.2m (31 December 2009: Β£11.1m).

Β 

The Board is encouraged by the rate of adoption of the Group's P3 products in new markets and remains satisfied with the relative stability of P1 sales in Xaar's traditional markets. The Board is now looking forward to volume sales of both P3 and new P1 products across a wider range of customers and end markets together with the reduction of new product support costs.

Β 

Β 

Ends

Β 

Β 

Β 

Β 

CONTACTS

Β 

Xaar plc:

01223-423663

Ian Dinwoodie, Chief Executive

www.xaar.com

Andrew Taylor, Finance Director

Singer Capital Markets Limited:

020-3205-7500

Shaun Dobson

Bankside Consultants:

Steve Liebmann or Andy Harris

020-7367-8883 / 07802-888159

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSBBGDSBUBBGGL
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.